David Spiegel

This inventor holds 43 USPTO granted patents and 22 published patent applications, plus 1 CIPO patent and 3 EPO patents, primarily in Cancer Therapeutics. Top assignees: Yale University, Kleo Pharmaceuticals, Inc., Biohaven Therapeutics Ltd.. Active years: 1980-2026.

USPTO Granted Patents = 43 (Patent Applications = 22)

% Patents Active = 97.7

CIPO Patents = 1 (Patent Applications = 9)

EPO Patents = 3 (Patent Applications = 13)

Average Co-Inventor Count = 2.3

ph-index = 6

Forward Citations = 173(Granted Patents)

Location History:

Willow Grove, PA (US) (1980)
Hamden, CT (US) (2020 - 2023)
New Haven, CT (US) (2014 - 2024)

Company Filing History:

Kleo Pharmaceuticals, Inc.

patents

1 out of 32

Biohaven Therapeutics Ltd.

patents

4. 2 out of 834,307

Other

patents

where one patent can have more than one assignee

Years Active: 1980-2026

Loading Chart...

Areas of Expertise:

Bifunctional Molecules

Antibody-Recruiting

Cancer Treatment

Chimeric Small Molecules

Synthetic Antibody Mimetic

Therapeutic DNP Derivatives

Cytotoxic-Drug Delivering

TLR-Agonist-Conjugated

Molecular Degraders

Selective Degradation

Urokinase Reprogramming

HIV Targeting

43 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12697391 - Bi-functional Molecules to Degrade Circulating Proteins (2026-08-04),

2. 12485178 - Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins (2025-12-02),

3. 12364766 - Bifunctional small molecules to target the selective degradation of circulating proteins (2025-07-22),

4. 12312621 - Reprogramming urokinase into an antibody-recruiting anticancer agent (2025-05-27),

5. 12234256 - Molecular degraders of extracellular proteins (2025-02-25),

6. 12168639 - Therapeutic DNP derivatives and methods using same (2024-12-17),

7. 12162892 - CD16a binding agents and uses thereof (2024-12-10),

8. 12128105 - Molecular degraders of extracellular proteins (2024-10-29),

9. 12084517 - Chimeric small molecules for the recruitment of antibodies to cancer cells (2024-09-10),

10. 12083181 - Bi-functional molecules to degrade circulating proteins (2024-09-10),

11. 12042542 - Synthetic antibody mimetic compounds (SYAMS) targeting cancer, especially prostate cancer (2024-07-23),

12. 11920172 - Reprogramming urokinase into an antibody-recruiting anticancer agent (2024-03-05),

13. 11858917 - Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus (2024-01-02),

14. 11767301 - Bi-functional molecules to degrade circulating proteins (2023-09-26),

15. 11725064 - Chimeric small molecules for the recruitment of antibodies to cancer cells (2023-08-15),

Title: The Innovative Mind of David Spiegel

Introduction: David Spiegel, a talented inventor hailing from New Haven, CT, is known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: David Spiegel holds several patents in the realm of artificial intelligence and renewable energy technologies, showcasing his commitment to creating a sustainable future.

Career Highlights: With a career spanning over two decades, David Spiegel has worked with top research institutions and leading tech companies to bring his inventions to life. His innovative spirit has led to the development of cutting-edge solutions that have revolutionized various industries.

Collaborations: Throughout his career, David Spiegel has collaborated with renowned scientists, engineers, and entrepreneurs to push the boundaries of technological advancement. His ability to work in multidisciplinary teams has resulted in the successful implementation of numerous projects.

Conclusion: David Spiegel's passion for innovation and his relentless drive to create a positive impact on society through his inventions make him a true pioneer in the world of technology. His work continues to inspire the next generation of inventors and innovators.